1. Home
  2. MDWD vs IDR Comparison

MDWD vs IDR Comparison

Compare MDWD & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • IDR
  • Stock Information
  • Founded
  • MDWD 2000
  • IDR 1996
  • Country
  • MDWD Israel
  • IDR United States
  • Employees
  • MDWD N/A
  • IDR N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • IDR Precious Metals
  • Sector
  • MDWD Health Care
  • IDR Basic Materials
  • Exchange
  • MDWD Nasdaq
  • IDR Nasdaq
  • Market Cap
  • MDWD 184.8M
  • IDR 174.3M
  • IPO Year
  • MDWD 2014
  • IDR N/A
  • Fundamental
  • Price
  • MDWD $17.75
  • IDR $10.35
  • Analyst Decision
  • MDWD Strong Buy
  • IDR Strong Buy
  • Analyst Count
  • MDWD 1
  • IDR 1
  • Target Price
  • MDWD $25.00
  • IDR $14.00
  • AVG Volume (30 Days)
  • MDWD 56.9K
  • IDR 150.8K
  • Earning Date
  • MDWD 11-26-2024
  • IDR 11-04-2024
  • Dividend Yield
  • MDWD N/A
  • IDR N/A
  • EPS Growth
  • MDWD N/A
  • IDR 344.27
  • EPS
  • MDWD N/A
  • IDR 0.52
  • Revenue
  • MDWD $19,720,000.00
  • IDR $21,955,008.00
  • Revenue This Year
  • MDWD $10.37
  • IDR $100.42
  • Revenue Next Year
  • MDWD $26.36
  • IDR $4.80
  • P/E Ratio
  • MDWD N/A
  • IDR $20.51
  • Revenue Growth
  • MDWD N/A
  • IDR 64.93
  • 52 Week Low
  • MDWD $11.04
  • IDR $5.66
  • 52 Week High
  • MDWD $24.00
  • IDR $18.35
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 53.40
  • IDR 39.79
  • Support Level
  • MDWD $17.33
  • IDR $9.67
  • Resistance Level
  • MDWD $18.25
  • IDR $10.73
  • Average True Range (ATR)
  • MDWD 0.75
  • IDR 0.49
  • MACD
  • MDWD 0.05
  • IDR 0.06
  • Stochastic Oscillator
  • MDWD 73.68
  • IDR 30.28

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About IDR Idaho Strategic Resources Inc.

Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.

Share on Social Networks: